



FOR IMMEDIATE RELEASE:

EyeGate Pharma to Present Data on the EyeGate® II Ophthalmic Delivery System at ARVO 2008 Annual Meeting

Waltham, MA, – April 24, 2008 – EyeGate Pharma, a privately held, specialty pharmaceutical company using iontophoresis technology to safely and non-invasively deliver therapeutics into the front and back of the eye for treating serious ocular diseases, today announced that the company will be presenting two abstracts at the *Association for Research in Vision and Ophthalmology (ARVO) 2008 Annual Meeting*. ARVO takes place April 27 through May 1, 2008 at the Greater Fort Lauderdale/Broward County Convention Center in Ft. Lauderdale, FL.

The two poster presentations include, poster #98/A125, which will be presented on Sunday, April 27, 2008 from 8:30 - 10:15 AM in Hall B/C and poster #1813/D693, which will be presented on Monday, April 28, 2008 from 11:15 AM - 1:00 PM in Hall B/C.

For more information, please visit <https://www.arvo.org/eweb/startpage.aspx?site=AM2008>

About the EyeGate® II Delivery System

The EyeGate® II Delivery System works through iontophoresis, a technology currently used to transdermally deliver certain pain medications, such as fentanyl, anti-inflammatories and corticosteroids. EyeGate is addressing the need for a patient-friendly alternative mode of ocular drug delivery because there are safety and efficacy drawbacks posed by current ocular delivery applications, such as eyedrops, injections or implants, which are hindered by low bioavailability, collateral toxicities, sight-threatening infections and/or retinal damage. Non-invasive iontophoretic drug delivery occurs through enhanced transport of molecules through cells and tissues using the driving force of an applied electric field. To deliver a therapeutic to both the anterior and posterior tissues of the eye, the drug must initially be specially adapted for iontophoretic delivery. EyeGate has concentrated its efforts on optimizing the EyeGate® II Delivery System to deliver a wide range of therapeutics while developing a highly specialized laboratory dedicated to formulating drugs for iontophoretic delivery.

-more-

About EyeGate Pharma

EyeGate Pharma has recently initiated a Phase I clinical study designed to assess the safety and tolerability of the non-invasive EyeGate® II Ocular Drug Delivery System and plans to initiate Phase 2 clinical trials in the first half 2008 in uveitis and dry eye. EyeGate was founded in 1999 with technology licensed from Bascom Palmer Eye Institute at the University of Miami. EyeGate's transscleral (white membrane of the eye) iontophoresis delivery platform, the EyeGate® II Delivery System, was developed to safely deliver a wide range of therapeutics to both the anterior (front) and posterior (back) chambers of the eye. For more information please visit www.eyegatepharma.com.

#

IR/PR Contact:

Bryan Murphy or Tim Allison
LaVoie Group
978-745-4200 X105 or X102
bmurphy@lavoiegroup.com or
tallison@lavoiegroup.com